retatrutide triple agonist Today, we shared new data from two Phase 3 trials of retatrutide, our investigational agonist. Learn more at our link in bio Retatrutide: The first-in-class investigational triple

Whilst mild and transient bowel changes are an expected feature of retatrutide treatment, certain symptoms should prompt timely medical attention

Phase 2 data in patients with type 2 diabetes demonstrated HbA1c reductions of up to 2.16% at the 12mg dose after 36 weeks, along with 16.9% body weight reduction

* Always check with your clinician before starting new products

The risk is not eating enough protein, which leads to muscle loss alongside fat loss a bad outcome

Research shows that these injections may lead to improvements in metabolic health, including: Better blood sugar control Reduced cholesterol levels Lower blood pressure These benefits are particularly significant for individuals with weight-related conditions

Another study found that liraglutide also reduced the activation of microglial cells in the brain's cortex and thalamus in diabetic rats by lowering the expression of NLRP3 protein, a marker of inflammation in brain microglia [104]